Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens
Emanuel Gonçalves(European Bioinformatics Institute), Mathew J. Garnett(Wellcome Sanger Institute), Elizabeth A. Coker(Wellcome Sanger Institute), Andrew R. Leach(LifeArc), Gabriele Picco(Wellcome Sanger Institute), Fiona M. Behan(Age UK), Patricia Jaaks(Wellcome Sanger Institute), Clare Pacini(Wellcome Sanger Institute), Claire Crafter(AstraZeneca (United Kingdom)), Aldo Segura‐Cabrera(European Bioinformatics Institute), Howard Lightfoot(Wellcome Sanger Institute), Ben Sidders(AstraZeneca (United Kingdom)), Francesco Iorio(Human Technopole), Andrew Barthorpe(Wellcome Sanger Institute), Stephen E. Fawell(AstraZeneca (United States)), James T. Lynch(AstraZeneca (United Kingdom))
Cited by 16
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
|Journal of Molecular Biology|1997|6.7k
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
ChEMBL: towards direct deposition of bioassay data
|Nucleic Acids Research|2018|2.5k